Last $0.91 USD
Change Today -0.0055 / -0.60%
Volume 211.5K
CVM On Other Exchanges
Symbol
Exchange
NYSE Amex
Stuttgart
As of 2:37 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

cel-sci corp (CVM) Snapshot

Open
$0.92
Previous Close
$0.92
Day High
$0.94
Day Low
$0.91
52 Week High
09/24/13 - $2.05
52 Week Low
12/19/13 - $0.53
Market Cap
72.7M
Average Volume 10 Days
267.3K
EPS TTM
$-0.82
Shares Outstanding
79.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEL-SCI CORP (CVM)

Related News

No related news articles were found.

cel-sci corp (CVM) Related Businessweek News

No Related Businessweek News Found

cel-sci corp (CVM) Details

CEL-SCI Corporation is engaged in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. In addition, it is developing Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, is developing a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

cel-sci corp (CVM) Top Compensated Officers

Chief Executive Officer, Principal Financial ...
Total Annual Compensation: $439.1K
Founder, Chairman and President
Total Annual Compensation: $332.8K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $202.3K
Senior Vice President of Research - Cellular ...
Total Annual Compensation: $205.0K
Senior Vice President of Regulatory Affairs
Total Annual Compensation: $189.8K
Compensation as of Fiscal Year 2013.

cel-sci corp (CVM) Key Developments

CEL-SCI Corporation Expands Phase III Head and Neck Cancer Clinical

CEL-SCI Corporation announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine has added Centre Hospitalier Universitaire de Quebec (CHUQ)'s L'Hotel Dieu de Quebec to its growing number of clinical sites in North America. CHUQ is a network of three teaching hospitals affiliated with the medical school of Université Laval and several specialized institutions in Quebec City. CEL-SCI plans to activate additional clinical sites for accelerated patient enrollment in Canada. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. CEL-SCI's Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients.

CEL-SCI Corporation Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014

CEL-SCI Corporation announced unaudited earnings results for the third quarter and nine months ended June 30, 2014. The company reported an operating loss of $6,901,329 for the quarter ended June 30, 2014 versus an operating loss of $5,513,199 for the quarter ended June 30, 2013. Net loss available to common shareholders for the quarter was $2,444,480 or $0.11 per diluted share versus $4,507,074 or $0.18 per diluted share during the quarter ended June 30, 2013. Operating loss for the nine months ended June 30, 2014 was $19,062,074 versus $14,796,535 during the nine months ended June 30, 2013. The rise in operating loss was mostly attributable to an increase in research and development expenses to $12,627,269 in the nine month ended June 30, 2014 compared to $9,208,900 in the nine months ended June 30, 2013. The net loss available to common shareholders for the nine months was $21,261,925 or $0.38 per diluted share, versus $7,530,621 or $0.50 per diluted share during the same nine months ended June 30, 2013. The increase in net loss for the three and nine month periods of 2014 as compared to the same periods in 2013 was primarily attributable to a non-cash charge for the change in value of derivative instruments caused by the fluctuation in the Company's common stock share price.

CEL-SCI Corporation Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey

CEL-SCI Corporation announced that Turkey's Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection). The Company expects to enroll patients through three clinical centers in Turkey. Turkey thus becomes the 16(th) country to participate in the world's large Phase III head and neck cancer trial. Head and neck cancer accounts for about 6% of all cancers, with approximately 600,000 new cases reported annually worldwide. CEL-SCI has received U.S. Orphan Drug designation for Multikine in head and neck cancer in the US. Further expansion of the Phase III trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers by the end of 2015. Over 220 patients have been enrolled in the study to date. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine (Leukocyte Interleukin, Injection) is an immunotherapeutic agent that is being tested in a randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100-110 clinical centers in about 20 countries.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVM:US $0.91 USD -0.0055

CVM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CVM.
View Industry Companies
 

Industry Analysis

CVM

Industry Average

Valuation CVM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 279.9x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 272.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEL-SCI CORP, please visit www.cel-sci.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.